Product Datasheet
www.leinco.com

Leinco Technologies, Inc.
excellence in early discovery research™

Human PD-L1
Recombinant Protein

Product Information

Product No.: P614

Storage: *-20°C to -80°C*

Product Description

Background:

Human Programmed Death-Ligand 1 (PD-L1) is a protein that is a part of the immune checkpoint pathway which regulates the system used to balance the interaction between tumor cells and immune surveillance 1. Unlike PD-1, which is mainly found on T-cells and acts as a receptor, PD-L1 is predominantly present on tumor cells and antigen-presenting cells. It serves as a mediator of immune tolerance by exploiting natural pathways that prevent autoimmunity. Tumors can evade the immune system and avoid detection by expressing PD-L1, inhibiting T-cell activation[2]. Inflammatory cytokines in the tumor microenvironment further enhance this evasion strategy by increasing PD-L1 expression[3]. This highlights how tumors adapt and utilize the body's checkpoints for survival and growth. The complex involvement of PD-L1 in both tolerance and cancer immunoevasion emphasizes its significance as a target, for therapy. Blocking PD-L1 aims to dismantle the shield it provides to tumors allowing the immune system to regain its ability to eliminate cells[4].

Expression Host:

HEK-293 Cells

Format:

Purified No Carrier Protein

Storage and Stability

This lyophilized protein is stable for twelve months when stored at -20°C to -70°C. After aseptic reconstitution, this protein may be stored for one month at 2°C to 8°C or for three months at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

Applications

Applications and Recommended Usage (Quality Tested By Leinco):
SDS-PAGE,
WB,
ELISA,
FA

Country of Origin

USA

References

1. Yi M, Niu M, Xu L, Luo S, Wu K. J Hematol Oncol. 2021;14(1):10.
2. McDermott DF, Atkins MB. Cancer Medicine. 2013;2(5):662-673.
3. Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. Journal of Cellular Physiology. 2019;234(2):1313-1325.
4. Dong Y, Sun Q, Zhang X. Oncotarget. 2017;8(2):2171-2186.